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Edited by Sandro SonninoAbstract Human renal cell carcinoma (RCC) has been char-
acterized by remarkable changes in ganglioside composition.
TOS1 cells, typical of metastatic RCC, are characterized by
predominance of GM2 as monosialoganglioside, and b1,4Gal-
NAc disialyl-Lc4 (RM2 antigen) as disialoganglioside [J. Biol.
Chem. 276 (2001) 16695]. In order to observe the functional role
of gangliosides in RCC malignancy, TOS1 cells were transfected
with short interfering RNA (siRNA) based on open reading
frame sequence of b1,4GalNAc transferase (b1,4GalNAc-T),
and its disordered sequence of siRNA (dsiRNA) as control. In
siRNA transfectant, b1,4GalNAc-T mRNA level and GM2
expression were greatly reduced, whereby GM3 expression
appeared. In contrast, RM2 antigen level was unchanged, even
though it has the same b1,4GalNAc epitope at the terminus.
dsiRNA transfectant showed no change of b1,4GalNAc-T
mRNA and did not express GM3. Concomitant with reduction
of GM2 and appearance of GM3, siRNA transfectant showed
greatly reduced motility and invasiveness, although growth rate
was unaltered. Both transfectants with siRNA and dsiRNA
expressed the same level of tetraspanin CD9. Since CD9/GM3
complex is known to reduce integrin-dependent motility and
invasiveness [Biochemistry 40 (2001) 6414], it is plausible that
motility and invasiveness of siRNA transfectant of TOS1 cells
may be reduced by enhanced formation of such complex.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Metastatic/invasive properties of renal cell carcinoma (RCC)
have been suggested to correlate with ganglioside proﬁle [1,2].
RCC TOS1 cells [3] are highly metastatic and are characterized* Corresponding author. Fax: +81-22-717-7283.
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siRNA; b1,4GalNAc-T, b1,4GalNAc transferase; GAPDH, glyceral-
dehyde 6-phosphate dehydrogenase; GSL, glycosphingolipid; mAb,
monoclonal antibody; PCR, polymerase chain reaction; RCC, renal
cell carcinoma; siRNA, short interfering RNA; TLC, thin-layer
chromatography
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loganglioside, and by the absence of GM3. TOS1 cells also
contain a novel disialoganglioside b1,4GalNAc disialyl Lc4 [4]
deﬁned by monoclonal antibody (mAb) RM2 [5]. GM2 and
RM2 antigens have common terminal b1,4GalNAc structure.
RM2 antigen was previously claimed to be an adhesion re-
ceptor [3], or to be recognized by siglec-7, promoting metas-
tasis to lung [6]. On the other hand, GM2 in other types of
tumors has been implicated as a promoter of tumor cell in-
vasiveness (see Section 4). In order to clarify the role of GM2
and b1,4GalNAc disialyl Lc4 in deﬁning TOS1 cell phenotype,
we tried to ‘‘knock down’’ these gangliosides by sequence-
speciﬁc inhibition of b1,4GalNAc transferase (b1,4GalNAc-T)
gene [7], by transfecting short interfering RNA (siRNA) [8].
GM2 synthesis was clearly knocked down, with concomitant
appearance or enhancement of GM3, leading to reduction of
cell motility and invasiveness, presumably due to formation of
a complex with tetraspanin CD9, which inhibits integrin-de-
pendent cell motility and invasiveness [9–11]. However, the
level of RM2 antigen was unchanged by siRNA of b1,4Gal-
NAc-T, even though it has the same terminal structure (see
Section 4).2. Materials and methods
2.1. Synthesis of siRNA
The sequence of siRNA for human b1,4GalNAc-T cDNA (Gen-
Bank Accession No. M83651) according to the AA-N19 [N, any nu-
cleotide (nt)] rule was 50-GGAGCAAGUAGUGGGGCUGdTdT-30
(sense), 30-dTdTCCUCGUUCAUCACCCCGAC-50 (antisense).
Disordered siRNA (dsiRNA) of scrambled nucleotide sequence, used
as negative control, was 50-GCGCGCUUUGUAGGAUUCGdTdT-30
(sense), 30-dTdTCGCGCGAAACAUCCUAAGC-50 (antisense).
Speciﬁcity of the 21-nt sequences was conﬁrmed by BLAST search
against the human genome sequence. The RNA duplexes were pur-
chased from B-Bridge Japan (Tokyo, Japan).
2.2. Cell line and transfection
Human RCC TOS1 was established from the soft tissue metastatic
lesion of RCC (spindle cell type and clear cell mixture type RCC) from
a 62-year-old man [3]. This cell line was maintained in MEM (Gibco
BRL, Rockville, MD, USA) supplemented with 2 mM L-glutamine,
penicillin G (100 units/ml), streptomycin (100 lg/ml), 10 mM HEPES
buﬀer solution (DOJINDO, Kumamoto, Japan) and 10% heat-inac-
tivated fetal bovine serum (ICN Biomedicals, Aurora, OH, USA).
TOS1 cells were placed at a density of 5 104 per 35-mm diameter
dish. One day later, TOS1 cells were transfected with 200 pmol siRNA,ation of European Biochemical Societies.
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cording to the protocol provided by Nihon Bioservice (Saitama, Ja-
pan). The medium was replaced with fresh medium 6 h after
transfection and gene silencing eﬀect was analyzed 3–4 days after
transfection by the following assays. All experiments were performed
in triplicate.
2.3. Quantitative real-time polymerase chain reaction
Total RNA was isolated from each transfectant using ISOGEN-LS
(Nippon Gene Co., Tokyo, Japan) according to the manufacturer’s
instructions. cDNA was prepared from 1 lg total RNA using cDNA
Synthesis kit for real-time polymerase chain reaction (RT-PCR)
(Roche Diagnostics, Penzberg, Germany) according to the manufac-
turer’s protocol, using the principle of FRET-based RT-PCR [12]. Five
micrograms of each cDNA was diluted to a volume of 20 lg PCR mix
(LightCycler FastStart DNA Master Hybridization Probes, Roche
Diagnostics) containing 3 mM MgCl2, primers, and probes. The se-
quences and ﬁnal concentrations of primers and probes in the reactionFig. 1. Reduced b1,4GalNAc-T gene expression in siRNA transfectant. Pan
control GAPDH gene (C) in siRNA transfectant (d) and dsiRNA transfecta
various concentrations and used as references [1–5]. The acceptor LCRed640
detected on Channel 2 (F2) and normalized with ﬂuorescein signal detected on
b1,4GalNAc-T (B) and for GAPDH (D). Ct values for siRNA transfectant (
Panel II. The expression of b1,4GalNAc-T was normalized to GAPDH
transfectant, deﬁned as 100%. P values calculated from Welch test were <0.mixtures were: b1,4GalNAc-T forward 50-CGCTGGGGATTTCT-
GACTGT-30 (0.5 lM); reverse 50-GAGGACTTGGCACTGGCTGT-30
(0.5 lM); probe 50-CCCACCACCCTGTGAGCACTCTACT-ﬂuo-30
(0.2 lM); probe 50-LCRed 640-GCTGTCCCTGAGCCTCTAG-
TTCCTCA-phos-30 (0.2 lM); glyceraldehyde 6-phosphate dehydro-
genase (GAPDH) forward 50-TGAACGGGAAGCTCACTGG-30 (0.5
lM); reverse 50-TCCACCACCCTGTTGCTGTA-30 (0.5 lM); probe
50-TCAACAGCGACACCCACTCCT-ﬂuo-30 (0.2 lM); probe 50-
LCRed640-CACCTTTGACGCTGGGGCT-phos-30 (0.2 lM).
Primers and probes were purchased from Nihon Gene Research
Labs Inc. (Sendai, Japan). For ampliﬁcation, initial denaturation at
95 C for 10 min was followed by b1,4GalNAc-T: 10 s at 95 C, 15 s at
62 C, 7 s at 72 C; GAPDH: 10 s at 95 C, 15 s at 62 C, and 9 s at 72
C, for 40 cycles. The expected size of the PCR products was conﬁrmed
by agarose gel electrophoresis (data not shown). The PCR products
ampliﬁed without the probes from TOS1 transfected with dsiRNA
were diluted at various folds and used as references. The threshold
cycle Ct was assessed using LightCycler software v. 3.5.el I. Quantitative RT-PCR analysis of b1,4GalNAc-T gene (A) and of
nt (). RT-PCR product from the control transfectant was diluted at
signal yielded by ﬂuorescence resonance energy transfer (FRET) was
Channel 1 (F1). Ct values of the reference were plotted vs. dilutions for
d) and dsiRNA transfectant () were plotted on the standard curves.
level. Percent expression was calculated relative to control dsiRNA
01.
Fig. 2. TLC proﬁle of GSLs from TOS1 cells with or without
b1,4GalNAc-T siRNA transfection or dsiRNA transfection Panel A.
TLC proﬁle of GSLs shown by orcinol-sulfuric acid staining of TOS1
cells. TOS1 cells transfected with b1,4GalNAc-T siRNA, or trans-
fected with dsiRNA (as control) were extracted, and GSL fractions
were separated and analyzed by TLC on ‘‘equal cell wet weight’’ basis,
developed in C/M/0.5% aqueous CaCl2 (50:40:10) and stained with
orcinol-sulfuric acid. Lane 1: Reference GSLs, from top to bottom:
GlcCer (CMH), LacCer (CDH), Gb3, GM3, and GM2. Lane 2:
Monosialoganglioside fraction of TOS1 dsiRNA transfectant. Lane 3:
Monosialoganglioside fraction of TOS1 b1,4GalNAc-T siRNA
transfectant. Lane 4: Neutral GSL fraction of TOS1 dsiRNA trans-
fectant. Lane 5: Neutral GSL fraction of TOS1 b1,4GalNAc-T siRNA
transfectant. Note that GM2 is the sole monosialoganglioside in
control dsiRNA transfectant (lane 2), but is greatly reduced in siRNA
transfectant (lane 3). In contrast, GM3 is nearly absent in lane 2, but
appears in lane 3. Panel B. TLC immunostaining with anti-GM2 mAb
MK1-8. Total gangliosides of TOS1 cell b1,4GalNAc-T siRNA
transfectant and dsiRNA transfectant were stained with mAb MK1-8.
Lane 1: Reference GSLs, GM2. Lane 2: Control TOS1 dsiRNA
transfectant. Lane 3: TOS1 b1,4GalNAc-T siRNA transfectant. Per-
cent expression was quantiﬁed by using Scion Image relative to control
dsiRNA transfectant, deﬁned as 100%. Relative mean density of MK1-
8 in siRNA transfectant as compared with dsiRNA transfectant was
30%. Panel C. TLC immunostaining with anti-GM3 mAb M2590.
Total gangliosides of TOS1 cell b1,4GalNAc-T siRNA transfectant
and dsiRNA transfectant were stained with mAb M2590. Lane 1:
Reference GSLs, GM3. Lane 2: Control TOS1 dsiRNA transfectant.
Lane 3: TOS1 b1,4GalNAc-T siRNA transfectant.
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immunostaining
Glycosphingolipids (GSLs) were extracted [4,11] and separated from
phospholipids by alkaline degradation of phospholipids [13,14], and
GSLs were analyzed by thin-layer chromatography (TLC) with im-
munostaining [13–16]. Brieﬂy, 2–5 107 cells (pelleted by centrifuga-
tion) were extracted twice with 2 ml isopropanol/hexane/water
(55:25:20 v/v/v) [4,11]. Extracts were evaporated to dryness under ni-
trogen stream, and phospholipids in the residue were dissolved in 2 ml
of 0.1 M NaOH in methanol (40 C, 2 h), neutralized with 200 ll of 1
N HCl, and shaken repeatedly with 2 ml hexane to eliminate fatty
acids. GSLs in the lower layer were further puriﬁed and desalted by
SepPak C18 cartridge (Millipore) [14]. Total GSL fraction thus ob-
tained was further separated by DEAE–Sephadex A25 column into
neutral GSLs, monosialosyl, disialosyl, and other fractions by stepwise
elution with various molarities of ammonium acetate in chloroform/
methanol (C/M)/water. Each fraction was dialyzed, lyophilized, dis-
solved in C/M 2:1, and subjected to TLC analysis [4,14]. Aliquot
quantities of GSL fractions placed on TLC for analysis were based on
equal wet cell weight (10 mg). E.g., wet weight of pelleted 3 107
TOS1 cells is usually 200 mg; GSL fraction derived therefrom is
dissolved in 100 ll C/M 2:1; 5 ll aliquot (equivalent to 10 mg wet cell
weight) is placed on each lane of TLC and analyzed. TLC was de-
veloped in C/M/0.5% aqueous CaCl2 (50:40:10) and visualized by
spraying with 0.5% orcinol in 2 N sulfuric acid, or immunostained
[15,16] using mAbs MK1-8 (anti-GM2) [17], M2590 (anti-GM3) [18],
and RM2 (anti-GalNAc disialyl-Lc4) [5]. Vector avidin–biotin solution
with Konica HRP-1000 was used, as described previously [4].
Mean density proﬁle of MK1-8 and RM2 of dsiRNA and siRNA
were quantiﬁed using Scion Image.
2.5. In vitro cell proliferation assay
72 h after transfection, cells were seeded in 96-well plates at a density
of 104 cells/ml in MEM containing 10% FCS and cultured. Cell
number was measured daily using a Cell Counting Kit (Wako Pure
Chemical Industries, Tokyo, Japan).
2.6. In vitro motility assay and invasion assay
Motility assay. 72 h after transfection, cells were detached, aliquots of
1 105 cells per 100 ll were placed in the inner compartment of
Transwell chamber (Costar, Cambridge, MA, USA; polycarbonate
ﬁlter, pore size 8 lm), and 600 ll MEM containing 30 lg ﬁbronectin
was placed in the outer compartment, to initiate motility assay (surface
levels of cell suspension and FN solution in inner and outer com-
partments were the same). Cells migrated to the lower surface of
membrane after 3 and 6 h were counted under Giemsa staining, and
mean values for 10 microscopic ﬁelds were plotted. P values were
calculated from Student’s t test.
Invasion assay through Matrigel. For invasion assay, 50 ll of
Matrigel stock solution was placed at the upper surface of ﬁlter
and dried at 37 C overnight. The Matrigel stock solution was 1
mg/ml (containing laminin-1 and -2, collagen-IV, and heparan sul-
fate; BD Biosciences, Bedford, MA). Cell suspension was placed in
the inner compartment, ad migration was determined as described
previously [19].
2.7. Determination of cell surface CD9 expression
Expression of tetraspanin CD9 at the surface of siRNA transfectant
and parental TOS1 cells was determined by ﬂow cytometry using anti-
human CD9 mouse mAb TP-82 (Nichirei, Tokyo, Japan).3. Results
3.1. Knock-down of b1,4GalNAc-T mRNA measured by
RT-PCR
We examined mRNA level of b1,4GalNAc-T in siRNA
transfectant and dsiRNA transfectant by RT-PCR using
LightCycler. GAPDH was used as internal control in each
sample and normalized by GAPDH expression level (Fig. 1,
panel I). Relative expression of b1,4GalNAc-T mRNA in
siRNA transfectant as compared with dsiRNA transfectantwas 50%. For details of procedure, see Section 2 and Fig. 1
legend.
3.2. Decrease of GM2 expression and concomitant increase of
GM3 in siRNA transfectant TOS1 cells
TLC pattern of gangliosides from b1,4GalNAc-T siRNA
transfectant showed greatly reduced expression of GM2 and
concomitant increase of GM3 (Fig. 2A, lane 3), whereas TLC
pattern from dsiRNA transfectant showed GM2 as the sole
monosialoganglioside, without GM3 (lane 2). Reduced GM2
and increased GM3 in siRNA transfectant was further con-
ﬁrmed by TLC immunostaining with mAbs MK1-8 (anti-
GM2) (Fig. 2B) and M2590 (anti-GM3) (Fig. 2C). Relative
mean density of MK1-8 in siRNA transfectant as compared
with dsiRNA transfectant was 30% (Fig. 2B).
Fig. 4. Confocal laser scanning microscopy of TOS1 cell siRNA
transfectant and control dsiRNA transfectant.
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transfectant
Relative mean density of RM2 in siRNA transfectant as
compared with dsiRNA transfectant was 60% (Fig. 3A).
Since RM2 antigen has b1,4GalNAc at terminal Gal of disi-
alyl-Lc4, which is the same structure as in GM2 ganglioside,
we analyzed the expression of RM2 in b1,4GalNAc siRNA
transfectant,and found that RM2 antigen was unaﬀected (Figs.
3B and C).
3.4. Diﬀerence in GM2 and GM3 expression in siRNA
transfectant compared to dsiRNA transfectant TOS1 cells
GM2 expression was clear in control dsiRNA transfectant
cells, but was much lower in siRNA transfectant (Fig. 4, upper
panels). In contrast, immunoﬂuorescence staining for GM3
was much higher in siRNA transfectant than in dsiRNA
transfectant (Fig. 4, lower panels). This reciprocal relationship
was observed in the majority of cells.Fig. 3. RM2 antigen expression of TOS1 cell siRNA transfectant and control dsiRNA transfectant. Panel A. TLC immunostaining with mAbs RM2.
Total gangliosides of TOS1 cell b1,4GalNAc-T siRNA transfectant and dsiRNA transfectant were stained with mAbs RM2. Lane 1: Reference
GSLs, RM2. Lane 2: Control TOS1 dsiRNA transfectant. Lane 3: TOS1 b1,4GalNAc-T siRNA transfectant. Percent expression was quantiﬁed by
using Scion Image relative to control dsiRNA transfectant, deﬁned as 100%. Relative mean density of RM2 in siRNA transfectant as compared with
dsiRNA transfectant was 60%. Panel B. RM2 expression, determined by ﬂow cytometry, of control TOS1 dsiRNA transfectant (left) and siRNA
transfectant (right). Panel C. Confocal laser scanning microscopy of TOS1 cell siRNA transfectant and control dsiRNA transfectant.
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Fig. 5. Motility, invasiveness, and cell growth of TOS1 b1,4GalNAc-T
siRNA transfectant compared to control dsiRNA transfectant Panel
A. FN-dependent Transwell motility of TOS1 b1,4GalNAc-T siRNA
transfectant (black square) compared to that of control dsiRNA
transfectant (open circle). Each transfectant was placed on three
Transwell plates and motility was determined by counting the number
of cells migrated to lower surface of membrane in ten microscopic
ﬁelds per plate (total 30 ﬁelds for each transfectant). Motility values at
3 and 6 h were determined, and Student’s t test and S.D. were calcu-
lated. In each case, P < 0:001. Panel B. Invasiveness through high
concentration of Matrigel (containing mainly laminin, collagen-IV,
and heparan sulfate) coated on Transwell membrane. Black square,
TOS1 b1,4GalNAc-T siRNA transfectant. Open circle, control dsiR-
NA. Procedures and statistical calculations as in Panel A. In each case,
P < 0:001. Panel C. Cell proliferation (growth curve) of TOS1
b1,4GalNAc-T siRNA transfectant (black square) compared to that of
control dsiRNA transfectant (open circle). Note that the growth rates
are essentially the same.
Fig. 6. CD9 expression, and CD9/GM3 expression ratio, in TOS1
b1,4GalNAc-T siRNA transfectant and parental TOS1 cells Panel A.
CD9 expression, determined by ﬂow cytometry, of parental TOS1 (left)
and siRNA transfectant (right). Panel B. GM3 expression, determined
by ﬂow cytometry, of parental TOS1 (left) and siRNA transfectant
(right).
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Matrigel of b1,4GalNAc siRNA transfectant as compared
to dsiRNA transfectant TOS1 cells
Fibronectin-dependent cell motility analyzed with Transwell
chamber was reduced in b1,4GalNAc siRNA transfectant as
compared to dsiRNA transfectant; the diﬀerence was much
greater at 6 than at 3 h after transfection (Fig. 5A). Cell mi-
gration through a high concentration of Matrigel (regarded as
‘‘invasion’’) was also greatly reduced in b1,4GalNAc siRNA
transfectant compared to control (Fig. 5B). Rate of cellproliferation as shown by cell growth curve of siRNA trans-
fectant was essentially the same as that of control dsiRNA
transfectant (Fig. 5C).
3.6. CD9 expression in b1,4GalNAc siRNA transfectant
Tetraspanin CD9, a type of proteolipid protein, was ex-
pressed to a similar, high degree in parental TOS1 cells and in
b1,4GalNAc siRNA transfectant, as observed by ﬂow cy-
tometry (Fig. 6A). Since GM3 is essentially absent in parental
TOS1 cells (Fig. 6B), relative expression of CD9 and GM3
(CD9/GM3 expression ratio) is greatly reduced in siRNA
transfectant. Cell motility is controlled by GM3/CD9/integrin
complex (see Section 4).4. Discussion
Tumor malignancy is closely associated with types of gan-
gliosides expressed. Bladder carcinoma with enhanced GM2
and lower GM3 expression showed higher motility and inva-
siveness [11]. Similarly, malignancy of mouse ependymoblas-
toma is higher in b1,4GalNAc transferase transfectant
expressing GM2 and other a-series gangliosides than in pa-
rental cells which express GM3 alone [20]. This relationship
between GM3 vs. GM2 expression as a basis of tumor cell
invasiveness is clariﬁed by the current studies with RCC TOS1
cells using siRNA approach. Our results show that silencing of
b1,4GalNAc-T by transfection of siRNA, but not dsiRNA as
control, knocks down GM2 expression and thereby increases
level of its precursor GM3. Associated with this change, siR-
NA transfectant showed signiﬁcant decrease of FN-dependent
cell motility and invasiveness through Matrigel. Since TOS1
cells have high CD9 expression, enhanced level of GM3 in
siRNA transfectant may cause formation of GM3/CD9/inte-
grin complex which suppresses integrin-dependent cell motil-
ity, as observed originally in ldlD cells with endogenous GM3
expression [9] and subsequently in various types of colorectal
208 H. Aoki et al. / FEBS Letters 567 (2004) 203–208carcinoma showing high CD9 expression, or transfected with
CD9 [10]. Extensive studies are necessary to clarify this
possibility.
TOS1 cells express novel b1,4GalNAc disialyl Lc4 (RM2
antigen), having the same terminal b1,4GalNAc as in GM2.
However, little change in the level of this ganglioside was
caused by siRNA approach with b1,4GalNAc-T, while GM2
was knocked down. This ﬁnding suggests that b1,4GalNAc-T
for synthesis of GM2 is diﬀerent from that for synthesis of
RM2 antigen in terms of substrate speciﬁcity. This point also
requires further extensive study.
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